Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BionX Medical Technologies Inc.

www.bionxmed.com

Latest From C2N Diagnostics LLC

Biogen Builds In Neurodegenerative Disease With Anti-Tau Deal

Biogen agreed to pay $300m upfront to buy a Phase II-ready tau antibody from Bristol. The plan is to move rapidly into mid-stage clinical trials for Alzheimer's disease and progressive supranuclear palsy.

Deals Neurology

Pipeline Watch: Phase III Trials For Daprodustat, Rovalpituzumab Tesirine

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Research & Development Approvals

Deals Shaping The Medical Industry, April 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.

BioPharmaceutical Medical Device

Deal Watch: Valeant Increases Bid, Wrests Salix Away From Endo

Janssen moves into a new generation of anticoagulation with X01 buyout. Lilly obtains Phase II-ready autoimmune candidate from South Korea’s Hanmi, which partnered a cancer compound with Spectrum just a week earlier, while AstraZeneca finds a commercialization partner for Movantik in Japan’s Daiichi Sankyo.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • BiOM
  • iWalk Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • BionX Medical Technologies Inc.
  • Senior Management
  • Charles S Carignan, CEO
    David Reissfelder, CFO
    Mark Chiappetta, SVP, R&D
    Matt Vitale, VP, Sales
    Tony Tremaglio, VP, Mktg.
  • Contact Info
  • BionX Medical Technologies Inc.
    Phone: (781) 761-1560
    4 Crosby Dr.
    Bedford, MA 01730
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register